Canadian Ebola drug trial stopped

A Canadian company that had been developing an Ebola drug says a clinical trial of the experimental product has been stopped.

No overall benefit shown from Tekmira's Ebola drug

A Canadian company that had been developing an Ebola drug says a clinical trial of the experimental product has been stopped.

Burnaby, B.C.-based Tekmira Pharmaceuticals says the trial was halted because it seemed clear that continuing was not likely to show that the drug works.

Tekmira Pharmaceuticals says a clinical trial of its experimental product was halted because it seemed clear that continuing was not likely to show that the drug works. (Edward Echwalu/Reuters)

The drug is called TKM-Ebola. It was being tested with Ebola patients in Sierra Leone.

Dr. Peter Horby, the chief investigator of the trial, says the drug has not been shown to benefit patients.

Horby says data from the trial still need to be analyzed.

Tekmira's experimental drug, TKM-Ebola, targets Ebola's genetic material. It is known as an RNA interference therapeutic.

Horby is with the University of Oxford, which was conducting the trial. The research was funded by Britain's Wellcome Trust charity.

With files from CBC News

Comments

To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.